Vital Therapies Inc (NASDAQ:VTL) shares were down 6.3% during trading on Monday . The company traded as low as $0.21 and last traded at $0.22. Approximately 1,933,147 shares changed hands during mid-day trading, an increase of 65% from the average daily volume of 1,170,231 shares. The stock had previously closed at $0.24.
A number of research analysts recently commented on VTL shares. Zacks Investment Research lowered Vital Therapies from a “buy” rating to a “hold” rating in a research note on Saturday, November 17th. ValuEngine lowered Vital Therapies from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th. Seven investment analysts have rated the stock with a hold rating, Vital Therapies presently has an average rating of “Hold” and an average target price of $12.00.
The stock has a market cap of $9.44 million, a price-to-earnings ratio of -0.17 and a beta of 3.54.
A number of large investors have recently made changes to their positions in VTL. BlackRock Inc. grew its position in Vital Therapies by 134.8% in the second quarter. BlackRock Inc. now owns 2,242,025 shares of the company’s stock valued at $15,356,000 after acquiring an additional 1,287,310 shares during the period. Vanguard Group Inc grew its position in Vital Therapies by 11.1% in the third quarter. Vanguard Group Inc now owns 1,481,908 shares of the company’s stock valued at $408,000 after acquiring an additional 148,016 shares during the period. Virtu Financial LLC grew its position in Vital Therapies by 120.3% in the fourth quarter. Virtu Financial LLC now owns 310,499 shares of the company’s stock valued at $58,000 after acquiring an additional 169,530 shares during the period. SG Americas Securities LLC bought a new stake in Vital Therapies in the fourth quarter valued at $37,000. Finally, Geode Capital Management LLC grew its position in Vital Therapies by 99.7% in the fourth quarter. Geode Capital Management LLC now owns 682,934 shares of the company’s stock valued at $127,000 after acquiring an additional 340,970 shares during the period. Hedge funds and other institutional investors own 21.10% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Vital Therapies (VTL) Stock Price Down 6.3%” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4165236/vital-therapies-vtl-stock-price-down-6-3.html.
Vital Therapies Company Profile (NASDAQ:VTL)
Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.
Recommended Story: Depreciation
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.